A study evaluating clinical benefit of 188 Rhenium-HEDP in routine clinical care of painful bone metastases in prostate and breast cancer patients.

Trial Profile

A study evaluating clinical benefit of 188 Rhenium-HEDP in routine clinical care of painful bone metastases in prostate and breast cancer patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Rhenium-188-etidronic acid (Primary)
  • Indications Bone metastases
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top